ArticleBMC microbiology2026
Antimicrobial resistance patterns of enteropathogens and probiotic potential of infant gut-derived lactic acid bacteria in Maroua (Far North Cameroon).
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal infections remain a major public health concern, particularly in regions where antibiotic misuse has accelerated antimicrobial resistance. Identifying safe alternatives including probiotics is therefore critical. This study aimed to evaluate the probiotic potential of lactic acid bacteria (LAB) isolated from the gut microbiota of infants under six months of age in Maroua, Cameroon. METHODOLOGY: We conducted a retrospective study of stool culture records from the Maroua Regional Hospital (from January 2020 to december 2024), followed by a cross-sectional laboratory study. Ten healthy infants provided stool samples, from which LAB were isolated on De Man, Rogosa and Sharpe (MRS) agar. Isolates were assessed for acid and bile salt tolerance, autoaggregation, and antimicrobial activity were tested using the agar well diffusion method.
resultsAmong 563 records, confirmed gastrointestinal infections accounted for 5.68% [3.78–7.58%]. Bacterial pathogens represented 28.14% (Salmonella enterica, Escherichia coli, Staphylococcus spp., Yersinia enterocolitica), parasites 25.01% (Trichomonas intestinalis, amoeba cysts), and fungi 46.87%. Enteropathogens showed multidrug resistance to fluoroquinolones (54.65%), and cephalosporins (42.86%), with complete sensitivity to carbapenems. LAB isolates demonstrated strong probiotic potential: survival at pH 2–5, tolerance to bile salts (0.3–1%), autoaggregation (61–81% at 24 h), and coaggregation with pathogens (62–81%). They inhibited E. coli, Proteus mirabilis, Salmonella spp., and Enterobacter cloacae, particularly in acidic supernatants. Biochemical identification revealed Lactiplantibacillus plantarum, L. pentosus, Lacticaseibacillus casei, and L. paracasei.
conclusionInfant-derived LAB strains exhibit promising probiotic properties and may serve as complementary strategies for preventing gastrointestinal infections. Further studies are needed to confirm their safety and clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.